Intervacc
0.90 SEK
+2.16 %
Less than 1K followers
IVACC
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+2.16 %
-6.83 %
-23.60 %
-16.51 %
-10.34 %
-59.65 %
-95.82 %
-97.41 %
-83.73 %
Intervacc is an animal health group that develops vaccines for animals. The company develops and sells vaccines against animal diseases based on its own technology platform with fused recombinant proteins. Sales are currently carried out through its own organization in the Nordic region and through its partner Dechra Pharmaceuticals in the rest of Europe. The company's headquarters are located in Hägersten.
Read moreMarket cap
306.73M SEK
Turnover
105.64K SEK
Revenue
11.79M
EBIT %
-655.47 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
17/2
2026
Annual report '25
All
Press releases
3rd party
ShowingAll content types
DNB Carnegie Access: Intervacc – Försäljningen i Q3 tar ett skutt uppåt
Intervacc: Delårsrapport januari - september 2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools